D. Matthews

发表

Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity

P. Rathod, John White, M. Phillips, 2016, Journal of medicinal chemistry.

A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.

David M. Shackleford, R. Price, P. Rathod, 2016, ACS infectious diseases.

Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1.

P. Charlton, N. Vicker, J. Golec, 2002, Bioorganic & medicinal chemistry letters.

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Juan A. Bueren-Calabuig, Andrei V. Pisliakov, David W. Gray, 2019, Proceedings of the National Academy of Sciences.

Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors

Jeremy N. Burrows, Werner Kaminsky, Margaret A. Phillips, 2014, Journal of medicinal chemistry.

Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.

David M. Shackleford, Susan A Charman, Pradipsinh K Rathod, 2011, Journal of medicinal chemistry.

Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.

David M. Shackleford, Francisco-Javier Gamo, Xiaoyi Deng, 2011, Journal of medicinal chemistry.

Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Yongyuth Yuthavong, Sumalee Kamchonwongpaisan, Jarunee Vanichtanankul, 2012, Proceedings of the National Academy of Sciences.

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13

Lisa K. Woolhiser, S. Norval, J. Sacchettini, 2017, Cell.

A Comparison by QSAR, Crystallography, and Computer Graphics of the Inhibition of Various Dihydrofolate Reductases by 5‐(X‐Benzyl)‐2,4‐diamino‐pyrimidines

R. Langridge, C. Hansch, J. Blaney, 1982 .

Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.

Aaron Shipway, L. Mattheakis, J. Nuss, 2012, Journal of medicinal chemistry.

The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.

P. Rathod, M. Phillips, D. Matthews, 2015, Acta crystallographica. Section F, Structural biology communications.

Medicinal Chemistry Case History: Discovery of the Dihydroorate Dehydrogenase Inhibitor DSM265 as an Antimalarial Drug Candidate

P. Rathod, M. Phillips, S. Charman, 2017 .

Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

Robert H Bates, L. Stojanovski, K. Read, 2021, Journal of medicinal chemistry.

Lead optimization of a pyrrole-based dihydroorotate dehydrogenase inhibitor series for the treatment of Malaria.

David M. Shackleford, P. Rathod, John White, 2020, Journal of medicinal chemistry.

The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.

P. Rathod, M. Phillips, D. Matthews, 2015, Acta crystallographica. Section F, Structural biology communications.